WO2009158412A3 - Sustained delivery of exenatide and other polypeptides - Google Patents

Sustained delivery of exenatide and other polypeptides Download PDF

Info

Publication number
WO2009158412A3
WO2009158412A3 PCT/US2009/048475 US2009048475W WO2009158412A3 WO 2009158412 A3 WO2009158412 A3 WO 2009158412A3 US 2009048475 W US2009048475 W US 2009048475W WO 2009158412 A3 WO2009158412 A3 WO 2009158412A3
Authority
WO
WIPO (PCT)
Prior art keywords
exenatide
polypeptides
sustained delivery
methods
implantable devices
Prior art date
Application number
PCT/US2009/048475
Other languages
French (fr)
Other versions
WO2009158412A8 (en
WO2009158412A2 (en
Inventor
Stefanie Decker
Harry Quandt
Peter Kuzma
Original Assignee
Endo Pharmaceuticals Solutions Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Endo Pharmaceuticals Solutions Inc. filed Critical Endo Pharmaceuticals Solutions Inc.
Priority to EP09770945.5A priority Critical patent/EP2303226B1/en
Priority to JP2011516610A priority patent/JP5622725B2/en
Publication of WO2009158412A2 publication Critical patent/WO2009158412A2/en
Publication of WO2009158412A3 publication Critical patent/WO2009158412A3/en
Publication of WO2009158412A8 publication Critical patent/WO2009158412A8/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0092—Hollow drug-filled fibres, tubes of the core-shell type, coated fibres, coated rods, microtubules or nanotubes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A61P5/08—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH for decreasing, blocking or antagonising the activity of the anterior pituitary hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin

Abstract

Described herein are implantable devices, formulations and methods of making implantable devices for the release of a polypeptide from an implantable device, and methods of use thereof.
PCT/US2009/048475 2008-06-25 2009-06-24 Sustained delivery of exenatide and other polypeptides WO2009158412A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
EP09770945.5A EP2303226B1 (en) 2008-06-25 2009-06-24 Sustained delivery of exenatide and other polypeptides
JP2011516610A JP5622725B2 (en) 2008-06-25 2009-06-24 Sustained delivery of exenatide and other polypeptides

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US7562508P 2008-06-25 2008-06-25
US61/075,625 2008-06-25

Publications (3)

Publication Number Publication Date
WO2009158412A2 WO2009158412A2 (en) 2009-12-30
WO2009158412A3 true WO2009158412A3 (en) 2010-07-15
WO2009158412A8 WO2009158412A8 (en) 2011-02-03

Family

ID=41111133

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2009/048475 WO2009158412A2 (en) 2008-06-25 2009-06-24 Sustained delivery of exenatide and other polypeptides

Country Status (4)

Country Link
US (3) US8071537B2 (en)
EP (1) EP2303226B1 (en)
JP (1) JP5622725B2 (en)
WO (1) WO2009158412A2 (en)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7759312B2 (en) * 2005-03-11 2010-07-20 Endo Pharmaceuticals Solutions Inc. Delivery of dry formulations of octreotide
AU2009262263B2 (en) * 2008-06-25 2014-08-14 Endo Pharmaceuticals Solutions Inc. Octreotide implant having a release agent
TWI583401B (en) 2011-10-24 2017-05-21 布雷本製藥股份有限公司 Implantable tizanidine compositions and methods of treatment thereof
KR102196009B1 (en) 2011-10-25 2021-01-04 프로테나 바이오사이언시즈 리미티드 Antibody formulations and methods
US11413329B2 (en) 2012-10-20 2022-08-16 Board Of Regents, The University Of Texas System Cancer cell trap
US9669405B2 (en) * 2012-10-22 2017-06-06 The Regents Of The University Of California Sterilizable photopolymer serum separator
WO2021173770A1 (en) 2020-02-28 2021-09-02 Nano Precision Medical, Inc. Polymeric stabilizing agents for implantable drug delivery devices
EP3297653B1 (en) 2015-05-22 2021-09-15 The Board of Trustees of the Leland Stanford Junior University Treatment of post-bariatric hypoglycemia with glp-1 antagonists
WO2017152014A1 (en) 2016-03-04 2017-09-08 Eiger Biopharmaceuticals, Inc. Treatment of hyperinsulinemic hypoglycemia with exendin-4 derivatives
WO2018094404A1 (en) 2016-11-21 2018-05-24 Eiger Biopharmaceuticals, Inc. Buffered formulations of exendin (9-39)
EP3565580B1 (en) * 2017-01-03 2024-03-06 i2o Therapeutics, Inc. Continuous administration of exenatide and co-adminstration of acetaminophen, ethinylestradiol or levonorgestrel
TWI829687B (en) 2018-05-07 2024-01-21 丹麥商諾佛 儂迪克股份有限公司 Solid compositions comprising a glp-1 agonist and a salt of n-(8-(2-hydroxybenzoyl)amino)caprylic acid
EP3801462A4 (en) 2018-05-24 2022-03-16 Celanese EVA Performance Polymers LLC Implantable device for sustained release of a macromolecular drug compound
KR20210013089A (en) 2018-05-24 2021-02-03 셀라니즈 이브이에이 퍼포먼스 폴리머스 엘엘씨 Implantable device for sustained release of macromolecular drug compounds
EP3810173A4 (en) * 2018-06-25 2022-03-30 Titan Pharmaceuticals, Inc. Implants for release of lipophilic or amphiphilic pharmaceutical substances
JP7167336B2 (en) * 2018-11-02 2022-11-08 バイオナット ラブス リミテッド Magneto-mechanical triggering of payload release from miniaturized devices
WO2024036108A1 (en) * 2022-08-09 2024-02-15 Bionaut Labs Ltd. Devices, systems, and methods for the treatment of malignant neoplasm disorders using controlled release devices

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004071736A2 (en) * 2003-02-13 2004-08-26 Matregen Corp. Method of producing structures using centrifugal forces
WO2005041873A2 (en) * 2003-10-24 2005-05-12 Azopax Therapeutics Llc Formulation of exendin-4
WO2006099288A2 (en) * 2005-03-11 2006-09-21 Indevus Pharmaceuticals, Inc. Controlled release formulations of octreotide
WO2008061355A1 (en) * 2006-11-24 2008-05-29 Matregen Corp. Glp-1 depot systems, and methods of manufacture and uses thereof
WO2008134475A2 (en) * 2007-04-27 2008-11-06 Endo Pharmaceuticals Solutions Inc., 33 Implant device release agents and methods of using same

Family Cites Families (93)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2265226A (en) 1936-10-17 1941-12-09 Du Pont Cast resins having integral sheen
US2513014A (en) * 1946-11-18 1950-06-27 Abbott Lab Apparatus for implanting medicinal pellets subcutaneously
GB1306541A (en) 1969-01-20 1973-02-14 Ceskoslovenska Akademie Ved Method of manufacturing tubes by centrifugal casting
US3921632A (en) * 1974-08-16 1975-11-25 Frank M Bardani Implant device
US4131604A (en) * 1977-11-23 1978-12-26 Thermo Electron Corporation Polyurethane elastomer for heart assist devices
US4285987A (en) * 1978-10-23 1981-08-25 Alza Corporation Process for manufacturing device with dispersion zone
US4298002A (en) * 1979-09-10 1981-11-03 National Patent Development Corporation Porous hydrophilic materials, chambers therefrom, and devices comprising such chambers and biologically active tissue and methods of preparation
US4386039A (en) * 1980-02-11 1983-05-31 Thermo Electron Corporation Process for forming an optically clear polyurethane lens or cornea
US4523005A (en) * 1981-10-30 1985-06-11 Thermedics, Inc. Extrudable polyurethane for prosthetic devices prepared from a diisocyanate, a polytetramethylene ether polyol, and 1,4-butane diol
US4751133A (en) 1984-11-13 1988-06-14 Thermedics, Inc. Medical patches and processes for producing same
US4860110A (en) * 1986-05-06 1989-08-22 Canon Kabushiki Kaisha Communication terminal device
US5342622A (en) * 1986-05-16 1994-08-30 The State Of Victoria Subdermal biocompatible implants
US4959217A (en) 1986-05-22 1990-09-25 Syntex (U.S.A.) Inc. Delayed/sustained release of macromolecules
US4743673A (en) * 1986-12-19 1988-05-10 Tyndale Plains-Hunter, Ltd. Hydrophilic carboxy polyurethanes
US4871094A (en) * 1986-12-31 1989-10-03 Alcon Laboratories, Inc. Means and method for dispensing substances
US4846793A (en) * 1987-03-18 1989-07-11 Endocon, Inc. Injector for implanting multiple pellet medicaments
US4994028A (en) 1987-03-18 1991-02-19 Endocon, Inc. Injector for inplanting multiple pellet medicaments
AU608891B2 (en) 1987-09-24 1991-04-18 Merck & Co., Inc. Solubility modulated drug delivery device
US5035891A (en) * 1987-10-05 1991-07-30 Syntex (U.S.A.) Inc. Controlled release subcutaneous implant
JPH01139525A (en) * 1987-11-27 1989-06-01 Sanwa Kagaku Kenkyusho Co Ltd Film preparation for external use and its production
US4954587A (en) * 1988-07-05 1990-09-04 Ciba-Geigy Corporation Dimethylacrylamide-copolymer hydrogels with high oxygen permeability
GB8820353D0 (en) * 1988-08-26 1988-09-28 Staniforth J N Controlled release tablet
IE64761B1 (en) 1989-02-16 1995-09-06 British Tech Group Dispensing device
PH30995A (en) * 1989-07-07 1997-12-23 Novartis Inc Sustained release formulations of water soluble peptides.
US5273752A (en) * 1989-07-18 1993-12-28 Alza Corporation Controlled release dispenser comprising beneficial agent
US5468811A (en) * 1989-11-02 1995-11-21 National Patent Development Corporation Hydrophilic composite polymer articles formed from a settable paste comprising a mixture of hydrophilic polymer and unsaturated monomer
JP2879695B2 (en) * 1990-02-22 1999-04-05 日本曹達株式会社 Oral mucosa-adhesive film preparation
US5254662A (en) * 1990-09-12 1993-10-19 Polymedia Industries, Inc. Biostable polyurethane products
JP2701977B2 (en) * 1990-09-28 1998-01-21 ファイザー インク Dosage form containing hydrophobic medium
US5266325A (en) * 1990-09-28 1993-11-30 Hydro Med Science Division Of National Patent Development Corp. Preparation of homogeneous hydrogel copolymers
AU651654B2 (en) * 1992-01-14 1994-07-28 Endo Pharmaceuticals Solutions Inc. Manufacture of water-swellable hydrophilic articles and drug delivery devices
HU222249B1 (en) * 1991-03-08 2003-05-28 Amylin Pharmaceuticals Inc. Process for producing amyline antagonistic peptide derivatives and pharmaceutical preparatives containing them
AU652984B2 (en) 1992-01-14 1994-09-15 Endo Pharmaceuticals Solutions Inc. Preparation of homogeneous hydrogel copolymers
JP2530079B2 (en) 1992-02-05 1996-09-04 ナショナル・パテント・ディベロプメント・コーポレーション Manufacture of water-swellable hydrophilic products and drug release devices
US5614223A (en) * 1992-05-04 1997-03-25 Digestive Care Inc. Intraoral medicament-releasing device
US5464933A (en) * 1993-06-07 1995-11-07 Duke University Synthetic peptide inhibitors of HIV transmission
DE69425781T2 (en) * 1993-06-11 2001-01-04 Nippon Chemicon Support and connection device for a magnetic field modulation head used in a photomagnetic recording
US5354835A (en) * 1993-07-23 1994-10-11 Saudi Basic Industries Corporation Desalination process
KR950007873A (en) * 1993-09-20 1995-04-15 후꾸하라 요시하루 Biologics Sustained-Release Pharmaceutical Formulations
JPH07252166A (en) 1993-09-20 1995-10-03 Shiseido Co Ltd Sustained release preparation
JPH0797338A (en) 1993-09-20 1995-04-11 Shiseido Co Ltd Sustained release preparation
NL9401051A (en) * 1994-06-24 1996-02-01 Stichting Tech Wetenschapp Microphone based on fluid flow measurement and acoustic generator based on it.
JPH0839586A (en) * 1994-07-27 1996-02-13 Banyu Pharmaceut Co Ltd Manufacture of release control formulation composition
US5904935A (en) 1995-06-07 1999-05-18 Alza Corporation Peptide/protein suspending formulations
US6143718A (en) * 1995-06-07 2000-11-07 Amylin Pharmaceuticals, Inc. Treatment of Type II diabetes mellutis with amylin agonists
US5817343A (en) * 1996-05-14 1998-10-06 Alkermes, Inc. Method for fabricating polymer-based controlled-release devices
ATE359805T1 (en) * 1996-08-30 2007-05-15 Peptech Ltd SUSTAINED RELEASE FORMULATION OF GNRH PEPTIDE AGONISTS AND ANALOGS
US5945128A (en) * 1996-09-04 1999-08-31 Romano Deghenghi Process to manufacture implants containing bioactive peptides
AUPO251096A0 (en) * 1996-09-23 1996-10-17 Cardiac Crc Nominees Pty Limited Polysiloxane-containing polyurethane elastomeric compositions
US5756127A (en) * 1996-10-29 1998-05-26 Wright Medical Technology, Inc. Implantable bioresorbable string of calcium sulfate beads
DK0996459T3 (en) * 1997-01-07 2006-01-16 Amylin Pharmaceuticals Inc Use of exendins and agonists thereof to reduce food intake
US5854127A (en) * 1997-03-13 1998-12-29 Micron Technology, Inc. Method of forming a contact landing pad
FI971385A0 (en) 1997-04-04 1997-04-04 Bioxid Oy Biocompatible composition, methodological method
US7101853B2 (en) * 1997-05-06 2006-09-05 Amylin Pharmaceuticals, Inc. Method for treating or preventing gastritis using amylin or amylin agonists
US7157555B1 (en) * 1997-08-08 2007-01-02 Amylin Pharmaceuticals, Inc. Exendin agonist compounds
US7220721B1 (en) * 1997-11-14 2007-05-22 Amylin Pharmaceuticals, Inc. Exendin agonist peptides
US6770623B1 (en) * 1997-12-09 2004-08-03 Eli Lilly And Company Stabilized teriparatide solutions
US6822016B2 (en) 2001-09-10 2004-11-23 Johnson & Johnson Vision Care, Inc. Biomedical devices containing internal wetting agents
WO2000004037A1 (en) * 1998-07-14 2000-01-27 Amylin Pharmaceuticals, Inc. Uncoupling protein 4 (ucp-4) and methods of use
EP2335706B1 (en) * 1998-07-23 2013-10-23 Southern Research Institute Preparation of thioarabinofuranosyl compounds
US6087334A (en) * 1998-08-21 2000-07-11 Amylin Pharmaceuticals, Inc. Anti-diabetic peptides
US20040071736A1 (en) * 1998-08-25 2004-04-15 Health Protection Agency Methods and compounds for the treatment of mucus hypersecretion
US7259136B2 (en) * 1999-04-30 2007-08-21 Amylin Pharmaceuticals, Inc. Compositions and methods for treating peripheral vascular disease
EP1658856B1 (en) * 1999-01-14 2010-03-17 Amylin Pharmaceuticals, Inc. Exendins for glucagon suppression
US6361797B1 (en) * 1999-01-28 2002-03-26 Hydro Med Sciences, Inc. Hydrogel compositions useful for the sustained release of macromolecules and methods of making same
JP2003519667A (en) * 2000-01-10 2003-06-24 アミリン・ファーマシューティカルズ，インコーポレイテッド Use of exendin and its agonists for modulating triglyceride levels and treating dyslipidemia
CN1487836A (en) * 2000-03-14 2004-04-07 埃米林药品公司 Effects of glucagon-like peptide-1 (7-36) on antro-pyloro-duodenal motility
KR100518046B1 (en) * 2000-05-19 2005-10-04 아밀린 파마슈티칼스, 인크. Treatment of acute coronary syndrome with glp-1
JP3498041B2 (en) * 2000-05-29 2004-02-16 科研製薬株式会社 Nasal formulation containing pralmorelin
US7118737B2 (en) * 2000-09-08 2006-10-10 Amylin Pharmaceuticals, Inc. Polymer-modified synthetic proteins
MXPA03005388A (en) * 2000-12-14 2003-09-25 Amylin Pharmaceuticals Inc Peptide yy and peptide yy agonists for treatment of metabolic disorders.
US20030049320A1 (en) 2000-12-18 2003-03-13 Wockhardt Limited Novel in-situ forming controlled release microcarrier delivery system
WO2002078597A2 (en) 2001-04-01 2002-10-10 Yeda Research And Development Co. Ltd. Weizmann Institute Of Science Oral absorbed drugs
US7105489B2 (en) * 2002-01-22 2006-09-12 Amylin Pharmaceuticals, Inc. Methods and compositions for treating polycystic ovary syndrome
DE10208335A1 (en) 2002-02-27 2003-09-04 Roehm Gmbh Pharmaceutical form and process for its preparation
AU2003243545A1 (en) * 2002-06-14 2003-12-31 Amylin Pharmaceuticals, Inc. Prevention and/or treatment of inflammatory bowel disease using pyy or agonists thereof
US20040097419A1 (en) * 2002-11-19 2004-05-20 Holger Petersen Organic compounds
US6942264B1 (en) * 2003-02-10 2005-09-13 Richard Mendez Disposable pet waste receptacle
CA2437639C (en) 2003-08-11 2016-07-05 Valera Pharmaceuticals, Inc. Long term drug delivery devices with polyurethane based polymers and their manufacture
US20050143303A1 (en) * 2003-12-26 2005-06-30 Nastech Pharmaceutical Company Inc. Intranasal administration of glucose-regulating peptides
US8076288B2 (en) * 2004-02-11 2011-12-13 Amylin Pharmaceuticals, Inc. Hybrid polypeptides having glucose lowering activity
JP2005350424A (en) * 2004-06-14 2005-12-22 Kyocera Chemical Corp Solid preparation and method for producing the same
WO2006009801A2 (en) * 2004-06-17 2006-01-26 Valera Pharmaceuticals, Inc. Compositions and methods for treating central precocious puberty
US7772182B2 (en) 2004-08-05 2010-08-10 Alza Corporation Stable suspension formulations of erythropoietin receptor agonists
SE0402345L (en) * 2004-09-24 2006-03-25 Mederio Ag Measured drug dose
JP2006249175A (en) * 2005-03-09 2006-09-21 Mitsubishi Engineering Plastics Corp Polycarbonate resin composition and medical equipment composed of it
US7759312B2 (en) * 2005-03-11 2010-07-20 Endo Pharmaceuticals Solutions Inc. Delivery of dry formulations of octreotide
FR2885813B1 (en) * 2005-05-19 2008-01-11 Oreal VECTORIZATION OF DSRNA BY CATIONIC PARTICLES AND THEIR USE ON SKIN MODEL.
US9095630B2 (en) 2005-05-19 2015-08-04 L'oreal Vectorization of dsRNA by cationic particles and use of same on a skin model
US20070037897A1 (en) 2005-08-12 2007-02-15 Guigui Wang Method for making contact lenses
JP2009507050A (en) 2005-09-08 2009-02-19 ガストロテック・ファルマ・アクティーゼルスカブ Use of GLP-1 molecules for the treatment of biliary dyskinesia and / or biliary pain / discomfort
EP1942869A2 (en) * 2005-11-04 2008-07-16 Eastman Chemical Company Carboxyalkyl cellulose esters for sustained delivery of pharmaceutically active substances
EP1984009B1 (en) * 2006-01-18 2012-10-24 Qps, Llc Pharmaceutical compositions with enhanced stability

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004071736A2 (en) * 2003-02-13 2004-08-26 Matregen Corp. Method of producing structures using centrifugal forces
WO2005041873A2 (en) * 2003-10-24 2005-05-12 Azopax Therapeutics Llc Formulation of exendin-4
WO2006099288A2 (en) * 2005-03-11 2006-09-21 Indevus Pharmaceuticals, Inc. Controlled release formulations of octreotide
WO2008061355A1 (en) * 2006-11-24 2008-05-29 Matregen Corp. Glp-1 depot systems, and methods of manufacture and uses thereof
WO2008134475A2 (en) * 2007-04-27 2008-11-06 Endo Pharmaceuticals Solutions Inc., 33 Implant device release agents and methods of using same

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
I. SPITZ ET AL.: "GnRH superanalog implants for prostate cancer", PROCEEDINGS OF THE 12TH INTERNATIONAL CONGRESS OF ENDOCRINOLOGY, LISBON,2004, 2004, Bologna, IT, pages 389 - 395, XP008122338 *

Also Published As

Publication number Publication date
JP2011526288A (en) 2011-10-06
EP2303226B1 (en) 2016-03-23
US20100292144A1 (en) 2010-11-18
US8475820B2 (en) 2013-07-02
EP2303226A2 (en) 2011-04-06
US20100021522A1 (en) 2010-01-28
WO2009158412A8 (en) 2011-02-03
US8071537B2 (en) 2011-12-06
JP5622725B2 (en) 2014-11-12
WO2009158412A2 (en) 2009-12-30
US9072786B2 (en) 2015-07-07
US20130252894A1 (en) 2013-09-26

Similar Documents

Publication Publication Date Title
WO2009158412A3 (en) Sustained delivery of exenatide and other polypeptides
MXPA06011924A (en) Polymer-based sustained release device.
EP2349086A4 (en) Devices, systems, and methods for endovascular staple and/or prosthesis delivery and implantation
EP2349087A4 (en) Devices, systems, and methods for endovascular staple and/or prosthesis delivery and implantation
GB2451769B (en) Devices, systems, and methods for medicament delivery
HK1136847A1 (en) Targeted integration into the ppp1r12c locus
WO2007121318A3 (en) Formulations for delivering insulin
WO2009117130A3 (en) Extended release forumulation containing a wax
WO2010105995A3 (en) Zoo-technical drug delivery device
WO2008121767A3 (en) Stitched polypeptides
PL2240220T3 (en) Implantable drug-delivery devices, and apparatus for refilling the devices
GB2449027B (en) Devices, systems and methods for medicament delivery
WO2011142858A3 (en) Chlorotoxin variants, conjugates, and methods for their use
GB0822532D0 (en) Devices,systems and methods for medicament delivery
HK1141441A1 (en) Sustained release pellets comprising wax-like material
WO2010027405A3 (en) Formulations of gc-c receptor agonist polypeptides
ZA201106620B (en) Axmi-001,axmi-002,axmi-030,axmi-035,and axmi-045:insecticidal proteins from bacillus thuringiensis and methods for their use
WO2010132370A8 (en) Soluble trem-1 family peptides and methods of use
WO2010043566A3 (en) Combination of an insulin and a glp-1 agonist
WO2007001888A3 (en) New regimens for controlled drug delivery devices for contraception
WO2008121508A3 (en) Implantable medical devices fabricated from block copolymers
WO2010006143A3 (en) Transdermal estrogen device and delivery
GB2477227B (en) Devices, systems and methods for medicament delivery
WO2009005718A8 (en) Polypeptide microparticles having sustained release characteristics, methods and uses
IL210218A (en) Formulation for the controlled release of octreotide after implantation, a kit comprising it and an implantable device comprising octreotide

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09770945

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: 2011516610

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2009770945

Country of ref document: EP